A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

@article{Hong2013API,
  title={A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors},
  author={David S. Hong and Razelle Kurzrock and Aung S. Naing and Jennifer J. Wheler and Gerald Steven Falchook and Jade S. Schiffman and Nathan Faulkner and Mary Jo Pilat and J. Christian O’Brien and Patricia A. Lorusso},
  journal={Investigational New Drugs},
  year={2013},
  volume={32},
  pages={436-444}
}
The aim of this study was to determine the maximum tolerated dose, dose-limiting toxicities, and pharmacokinetic profile of E7107 in patients with advanced solid tumors. Patients in this phase I, open-label, single-arm, dose-escalation study had metastatic or locally advanced solid tumors and received E7107 as a 30-minute intravenous infusion at doses of 0.6, 1.2, 1.8, 2.4, 3.2, 4.3, and 5.7 mg/m2. Twenty-six patients were enrolled in the study. At 5.7 mg/m2, two patients experienced dose… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 28 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 22 REFERENCES

Splicing factor SF3b as the molecular target of novel antitumor agent pladienolide [abstract 8211

  • Y Kotake, K Sagane, T Owa
  • Program and abstracts of the Twelfth Annual…
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…